Molecular glue degraders are a class of small molecules designed to selectively degrade proteins that contribute to disease, including those involved in cancer growth and immune system dysfunction, according to a Jan. 23 news release from the drugmaker.
Under the agreement, AbbVie will provide an upfront payment to Neomorph, which is also eligible for up to $1.64 billion in option fees and milestone payments, in addition to tiered royalties on any future product sales.
The collaboration combines AbbVie’s established capabilities in oncology and immunology with Neomorph’s molecular glue platform, the release said.
